150 related articles for article (PubMed ID: 16963260)
1. What clinicians need to know about antioestrogen resistance in breast cancer therapy.
Milano A; Dal Lago L; Sotiriou C; Piccart M; Cardoso F
Eur J Cancer; 2006 Nov; 42(16):2692-705. PubMed ID: 16963260
[TBL] [Abstract][Full Text] [Related]
2. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of tamoxifen resistance.
Ring A; Dowsett M
Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
[TBL] [Abstract][Full Text] [Related]
4. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.
Butt AJ; McNeil CM; Musgrove EA; Sutherland RL
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S47-59. PubMed ID: 16113099
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
[TBL] [Abstract][Full Text] [Related]
6. [Molecular aspects of different mechanisms of tamoxifen resistance].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL
Bull Cancer; 1997 Jan; 84(1):69-75. PubMed ID: 9180863
[TBL] [Abstract][Full Text] [Related]
7. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
J Clin Pathol; 2007 Apr; 60(4):397-404. PubMed ID: 16775123
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.
Moy B; Goss PE
Clin Cancer Res; 2006 Aug; 12(16):4790-3. PubMed ID: 16914563
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
Ishii Y; Waxman S; Germain D
Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
[TBL] [Abstract][Full Text] [Related]
10. Steroid hormone receptors and antineoplastic chemotherapy in human breast cancer.
Görlich M; Jandrig B
J Exp Clin Cancer Res; 1997 Mar; 16(1):95-103. PubMed ID: 9148869
[TBL] [Abstract][Full Text] [Related]
11. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
12. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
13. Predictors of response to systemic therapy in breast cancer.
Ring AE; Ellis PA
Forum (Genova); 2002; 12(1):19-32. PubMed ID: 12634908
[TBL] [Abstract][Full Text] [Related]
14. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?
Prowell TM; Armstrong DK
Semin Oncol; 2006 Dec; 33(6):681-7. PubMed ID: 17145348
[TBL] [Abstract][Full Text] [Related]
15. Resistance to endocrine therapy in breast cancer.
Kurebayashi J
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():39-46. PubMed ID: 16273353
[TBL] [Abstract][Full Text] [Related]
16. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
Bedard PL; Freedman OC; Howell A; Clemons M
Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
[TBL] [Abstract][Full Text] [Related]
17. The significance of estrogen receptors in tamoxifen and toremifene therapy.
Valavaara R; Kangas L
Ann Clin Res; 1988; 20(5):380-8. PubMed ID: 2975479
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
19. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
Giuliano M; Schifp R; Osborne CK; Trivedi MV
Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
